enumeral biomedical holdings (ENUM) Key Developments
Enumeral Receives Phase II Small Business Innovation Research (SBIR) contract from the National Cancer Institute to Advance Human Tissue Immuno-Oncology Profiling
Sep 17 14
Enumeral has been awarded a Phase II Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI) for $999,967 over two years. The company will be developing an advanced, automated prototype system for human tissue immuno-oncology profiling, which it will deploy at two leading medical institutions over the course of the contract. The NCI will be funding the entirety of the program, which will complement Enumeral's other internal research and development efforts. Small volume clinical specimens such as core biopsy or fine needle aspirates often contain limited numbers of cells and can be challenging to analyze with conventional technologies. This Phase II program utilizes Enumeral's platform to obtain multiplexed information from human tissue samples of limited cellularity, potentially addressing these challenges. Enumeral generated proof of concept in this area under a Phase I contract in 2012 and 2013.
Enumeral Appoints Kevin Sarney as Vice President of Finance and Chief Accounting Officer
Sep 15 14
Enumeral Biomedical Holdings, Inc. announced that Kevin Sarney, CPA, has been appointed Vice President of Finance and Chief Accounting Officer. Prior to joining Enumeral, Mr. Sarney served as Vice President, Finance and Administration at Avaxia Biologics.
Enumeral Biomedical Holdings, Inc. Amends Certificate of Incorporation
Aug 8 14
Prior to the closing of the Merger, Enumeral Biomedical Holdings, Inc. amended and restated its Certificate of Incorporation. The amendment was approved and adopted by the company's Board of Directors and stockholders. The effective date of the amendment was July 31, 2014.
Enumeral Biomedical Holdings, Inc. Announces Auditor Changes
Aug 8 14
Enumeral Biomedical Holdings, Inc. announced that on July 31, 2014, Anton & Chia, LLP, was dismissed as independent registered public accounting firm. On the same date, Friedman LLP was engaged as new independent registered public accounting firm.
Enumeral Biomedical Holdings, Inc. Announces Management Changes
Aug 8 14
On July 31, 2014 (Closing date), Enumeral Biomedical Holdings, Inc., Enumeral Acquisition Corp. and Enumeral Biomedical Corp. entered into an agreement and plan of merger and reorganization, which closed on the same date. On the closing date, Olesya Didenko, its sole director before the merger, resigned her position as a director, and Arthur H. Tinkelenberg, John J. Rydzewski, Daniel B. Wolfe, Allan Rothstein and Barry Buckland were appointed to the Board of Directors. Also on the closing date, Ms. Olesya Didenko, its President, Secretary and Treasurer before the merger, resigned from these positions, and John J. Rydzewski was appointed as Executive Chairman, Arthur H. Tinkelenberg was appointed as Chief Executive Officer and President, Derek Brand was appointed as Vice President of Business Development and Secretary, Anhco Nguyen was appointed as Vice President of Research and Development and Kevin Sarney has been appointed as Vice President of Finance and Chief Accounting Officer.